Improved tumor uptake by optimizing liposome based res blockade strategy

Theranostics

Volumn 7, Issue 2, 2017, Pages 319-328

  Sun, Xiaolian ^a,b   Yan, Xuefeng ^b   Jacobson, Orit ^b   Sun, Wenjing ^a   Wang, Zhantong ^a,b   Tong, Xiao ^b   Xia, Yuqiong ^b   Ling, Daishun ^c   Chen, Xiaoyuan ^b  

^a XIAMEN UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Enhanced tumor uptake; Liposome blockade; Nanoparticle; Positron Emission Tomography; Reticuloendothelial system

Indexed keywords

LIPOSOME; NANOMATERIAL; ANTINEOPLASTIC AGENT; COPPER; GOLD; NANOPARTICLE;

ARTICLE; ATOMIC EMISSION SPECTROMETRY; BIOCOMPATIBILITY; BRIGHT FIELD MICROSCOPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG TUMOR LEVEL; FILTRATION; HUMAN; HUMAN CELL; HYDRODYNAMICS; IMAGE ANALYSIS; IMAGE PROCESSING; LIVER; MACROPHAGE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; RETICULOENDOTHELIAL SYSTEM; SPLEEN; SYSTEMATIC REVIEW; THIN LAYER CHROMATOGRAPHY; ZETA POTENTIAL; ANIMAL; DIAGNOSTIC IMAGING; DISEASE MODEL; GLIOBLASTOMA; METABOLISM; MONONUCLEAR PHAGOCYTE; MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; COPPER RADIOISOTOPES; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; GOLD; LIPOSOMES; LIVER; MICE; MONONUCLEAR PHAGOCYTE SYSTEM; NANOPARTICLES; POSITRON-EMISSION TOMOGRAPHY; SPLEEN;

EID: 85008467335     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.18078     Document Type: Article

References (38)

1. Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical Translation of Nanomedicine. Chem. Rev. 2015; 115: 11147-11190.
2. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in Cancer Therapy: Challenges, Opportunities, and Clinical Applications. J. Control. Release 2015; 200: 138-157.
3. Caruso F, Hyeon T, Rotello VM. Nanomedicine. Chem. Soc. Rev. 2012; 41: 2537-2538.
4. Lim EK, Kim T, Paik S, Haam S, Huh YM, Lee K. Nanomaterials for Theranostics: Recent Advances and Future Challenges. Chem. Rev. 2014; 115: 327-394.
5. Ma X, Zhao Y, Liang XJ. Theranostic Nanoparticles Engineered for Clinic and Pharmaceutics. Acc. Chem. Res. 2011; 44: 1114-1122.
6. Ilium L, Davis S, Wilson C, Thomas N, Frier M, Hardy J. Blood Clearance and Organ Deposition of Intravenously Administered Colloidal Particles. The Effects of Particle Size, Nature and Shape. Int. J. Pharm. 1982; 12: 135-146.
7. Petros RA, DeSimone JM. Strategies in the Design of Nanoparticles for Therapeutic Applications. Nat. Rev. Drug Discov. 2010; 9: 615-627.
8. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of Nanoparticle Delivery to Tumours. Nat. Rev. Mater. 2016; 1: 16014.
9. Wang B, He X, Zhang Z, Zhao Y, Feng W. Metabolism of Nanomaterials in vivo: Blood Circulation and Organ Clearance. Acc. Chem. Res. 2012; 46: 761-769.
10. Yu M, Zheng J. Clearance Pathways and Tumor Targeting of Imaging Nanoparticles. ACS Nano 2015; 9: 6655-6674.
11. Ehlerding EB, Chen F, Cai W. Biodegradable and Renal Clearable Inorganic Nanoparticles. Adv. Sci. 2016; 3: 1500223.
12. Liu J, Yu M, Zhou C, Zheng J. Renal Clearable Inorganic Nanoparticles: a New Frontier of Bionanotechnology. Mater. Today 2013; 16: 477-486.
13. Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, et al. Multimodal Silica Nanoparticles are Effective Cancer-Targeted Probes in a Model of Human Melanoma. J. Clin. Invest. 2011; 121: 2768-2780.
14. Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, et al. Clinical Translation of an Ultrasmall Inorganic Optical-PET Imaging Nanoparticle Probe. Sci. Trans. Med. 2014; 6: 260ra149-260ra149.
15. Patel KR, Li MP, Baldeschwieler JD. Suppression of Liver Uptake of Liposomes by Dextran Sulfate 500. Proc. Natl. Acad. Sci. U S A 1983; 80: 6518-6522.
16. Tanaka T, Taneda K, Kobayashi H, Okumura K, Muranishi S, Sezaki H. Application of Liposomes to the Pharmaceutical Modification of the Distribution Characteristics of Drugs in the Rat. Chem. Pharm. Bull 1975; 23: 3069-3074.
17. Diagaradjane P, Deorukhkar A, Gelovani JG, Maru DM, Krishnan S. Gadolinium Chloride Augments Tumor-Specific Imaging of Targeted Quantum Dots in vivo. ACS Nano 2010; 4: 4131-4141.
18. Van Rooijen N, Van Nieuwmegen R. Elimination of Phagocytic Cells in the Spleen after Intravenous Injection of Liposome-Encapsulated Dichloromethylene Diphosphonate. Cell Tissue Res. 1984; 238: 355-358.
19. Allen TM, Cullis PR. Liposomal Drug Delivery Systems: from Concept to Clinical Applications. Adv. Drug Deliv. Rev. 2013; 65: 36-48.
20. Pattni BS, Chupin VV, Torchilin VP. New Developments in Liposomal Drug Delivery. Chem. Rev. 2015; 115: 10938-10966.
21. Lian T, Ho RJ. Trends and Developments in Liposome Drug Delivery Systems. J. Pharm. Sci. 2001; 90: 667-680.
22. Abra RM, Bosworth M, Hunt C. Liposome Disposition in vivo: Effects of Pre-dosing with Lipsomes. Res. Commun. Chem. Pathol. Pharmaco. 1980; 29: 349-360.
23. Liu T, Choi H, Zhou R, Chen IW. RES Blockade: A Strategy for Boosting Efficiency of Nanoparticle Drug. Nano Today 2015; 10: 11-21.
24. Huang X, Neretina S, El-Sayed MA. Gold Nanorods: from Synthesis and Properties to Biological and Biomedical Applications. Adv. Mater. 2009; 21: 4880-4910.
25. Sun X, Huang X, Yan X, Wang Y, Guo J, Jacobson O, et al. Chelator-Free 64Cu-Integrated Gold Nanomaterials for Positron Emission Tomography Imaging Guided Photothermal Cancer Therapy. ACS Nano 2014; 8: 8438-8446.
26. Song J, Yang X, Jacobson O, Huang P, Sun X, Lin L, et al. Ultrasmall Gold Nanorod Vesicles with Enhanced Tumor Accumulation and Fast Excretion from the Body for Cancer Therapy. Adv. Mater. 2015; 27: 4910-4917.
27. Liu D, Mori A, Huang L. Role of Liposome Size and RES Blockade in Controlling Biodistribution and Tumor Uptake of GM 1-Containing Liposomes. Biochim. Biophys. Acta 1992; 1104: 95-101.
28. Szoka F, Papahadjopoulos D. Procedure for Preparation of Liposomes with Large Internal Aqueous Space and High Capture by Reverse-Phase Evaporation. Proc. Natl. Acad. Sci. U S A 1978; 75: 4194-4198.
29. Ellens H, Mayhew E, Rustum YM. Reversible Depression of the Reticuloendothelial System by Liposomes. Biochim. Biophys. Acta 1982; 714: 479-485.
30. Gregoriadis G, Neerunjun DE. Control of the Rate of Hepatic Uptake and Catabolism of Liposome-Entrapped Proteins Injected into Rats. Possible Therapeutic Applications. Eur. J. Biochem. 1974; 47: 179-185.
31. Gregoriadis G, Neerunjun DE, Hunt R. Fate of a Liposome-Associated Agent Injected into Normal and Tumour-bearing Rodents. Attempts to Improve Localization in Tumour Tissues. Life Sci. 1977; 21: 357-369.
32. Saba TM. Physiology and Physiopathology of the Reticuloendothelial System. Arch. Intern. Med. 1970; 126: 1031-1052.
33. Petersen AL, Binderup T, Rasmussen P, Henriksen JR, et al: 64 Cu Loaded Liposomes as Positron Emission Tomography Imaging Agents. Biomaterials 2011; 32: 2334-2341.
34. Souhami RL, Patel HM, Ryman BE. The Effect of Reticuloendothelial Blockade on the Blood Clearance and Tissue Distribution of Liposomes. Biochim. Biophys. Acta 1981; 674: 354-371.
35. Naudí A, Jové M, Ayala V, Portero-Otín M, Barja G, Pamplona R, et al. Membrane Lipid Unsaturation as Physiological Adaptation to Animal Longevity. Front Physiol. 2013; 4: 372.
36. Mu Q, Jiang G, Chen L, Zhou H, Fourches D, Tropsha A. Chemical Basis of Interactions Between Engineered Nanoparticles and Biological Systems. Chem. Rev. 2014; 114: 7740-7781.
37. Kao YJ, Juliano RL. Interactions of Liposomes with the Reticuloendothelial System Effects of Reticuloendothelial Blockade on the Clearance of Large Unilamellar Vesicles. Biochim. Biophys. Acta 1981; 677: 453-461.
38. Wagner Jr HN, Iio M. Studies of the Reticuloendothelial System (RES). III. Blockade of the RES in Man. J. Clin. Invest. 1964; 43: 1525.